FUNDAMENTALS · Fundamentals · TW Healthcare

Handa Pharmaceuticals (6620) Fundamentals 2026 — P/E 21.2x, Revenue Analysis | SniperIQ

Handa Pharmaceuticals (6620) is a TW-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of NT

4.5B, trading at NT$86.90 on the TWO. This SniperIQ fundamentals page covers Handa Pharmaceuticals's valuation (P/E 21.2x, P/B 2.7x), profitability (net margin 43.7%), revenue (NT
.7B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT
4.5B
P/E (TTM)21.2x
Net Margin43.7%
Revenue (FY25)NT
.7B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Handa Pharmaceuticals's market cap?

Handa Pharmaceuticals (6620) has a market capitalization of approximately NT

4.5B, trading at NT$86.90 on the TWO. Market cap moves with the live share price.

What is Handa Pharmaceuticals's P/E ratio?

Handa Pharmaceuticals's trailing twelve-month P/E ratio is 21.2x, with a price-to-book (P/B) of 2.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Handa Pharmaceuticals?

Handa Pharmaceuticals runs a net profit margin of 43.7%, a gross margin of 83.3%, and an operating margin of 47.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Handa Pharmaceuticals generate?

Handa Pharmaceuticals reported revenue of NT

.7B for fiscal year 2025, with net income of NT$750M and earnings per share (EPS) of 4.85. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Handa Pharmaceuticals pay a dividend?

Handa Pharmaceuticals offers a trailing dividend yield of about 2.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Handa Pharmaceuticals financially healthy?

Handa Pharmaceuticals carries a debt-to-equity ratio of 0.01x and a current ratio of 8.91x, with a market beta of 0.69. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Handa Pharmaceuticals a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Handa Pharmaceuticals (6620) the key facts are: market cap NT

4.5B, P/E 21.2x, revenue NT
.7B, 52-week range 64.1-154. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Handa Pharmaceuticals's full fundamentals live

Get Handa Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Jagsonpal Pharmaceuticals (JAGSNPHARM) fundamentals · Shenyang Xingqi Pharmaceutical (300573) fundamentals · Shandong Weigao Group Medical Polymer (1066) fundamentals · Micro-Tech (Nanjing) (688029) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons